30 Day Trial

Kuros to Begin Fibrin-PTH Clinical Trial in Spinal Fusion


Kuros Biosciences gained FDA approval for its Investigational New Drug (IND) application to initiate a Phase IIA clinical trial to evaluate Fibrin-PTH orthobiologic material (KUR-113) in single level transforaminal lumbar interbody fusion to treat degenerative disc disease, with autograft as comparator.

This IND application is considered to be the first ever approval by FDA to evaluate a drug/biologic combination product candidate for lumbar interbody fusion.

The prospective, randomized, controlled, open-label, multi-center parallel group study has a primary endpoint of radiographic interbody fusion, using CT-scans at 12 months.

Source: Kuros Biosciences